Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial
Geltrude Mingrone,Annieke Cg van Baar,Jacques Devière,David Hopkins,Eduardo Moura,Cintia Cercato,Harith Rajagopalan,Juan Carlos Lopez-Talavera,Kelly White,Vijeta Bhambhani,Guido Costamagna,Rehan Haidry,Eduardo Grecco,Manoel Galvao Neto,Guruprasad Aithal,Alessandro Repici,Bu'Hussain Hayee,Amyn Haji,A John Morris,Raf Bisschops,Manil D Chouhan,Naomi S Sakai,Deepak L Bhatt,Arun J Sanyal,J J G H M Bergman,Investigators of the REVITA-2 Study,Ana Teresa Santomauro,Jacques Bergman,Max Nieuwdorp,John Morris,Russell Drummond,David Carty,Laurent Crenier,Andrea Lania,Nazerena Betella,Bu Hayee,Krish Ragunath,Iskander Idris,Carolyn Chee,Caterina Guidone,Rachel Batterham,Ann Mertens
DOI: https://doi.org/10.1136/gutjnl-2020-323608
IF: 24.5
Gut
Abstract:Objective: Hydrothermal duodenal mucosal resurfacing (DMR) is a safe, outpatient endoscopic procedure. REVITA-2, a double-blind, superiority randomised controlled trial, investigates safety and efficacy of DMR using the single catheter Revita system (Revita DMR (catheter and system)), on glycaemic control and liver fat content in type 2 diabetes (T2D). Design: Eligible patients (haemoglobin A1c (HbA1c) 59-86 mmol/mol, body mass index≥24 and ≤40 kg/m2, fasting insulin >48.6 pmol/L, ≥1 oral antidiabetic medication) enrolled in Europe and Brazil. Primary endpoints were safety, change from baseline in HbA1c at 24 weeks, and liver MRI proton-density fat fraction (MRI-PDFF) at 12 weeks. Results: Overall mITT (DMR n=56; sham n=52), 24 weeks post DMR, median (IQR) HbA1c change was -10.4 (18.6) mmol/mol in DMR group versus -7.1 (16.4) mmol/mol in sham group (p=0.147). In patients with baseline liver MRI-PDFF >5% (DMR n=48; sham n=43), 12-week post-DMR liver-fat change was -5.4 (5.6)% in DMR group versus -2.9 (6.2)% in sham group (p=0.096). Results from prespecified interaction testing and clinical parameter assessment showed heterogeneity between European (DMR n=39; sham n=37) and Brazilian (DMR n=17; sham n=16) populations (p=0.063); therefore, results were stratified by region. In European mITT, 24 weeks post DMR, median (IQR) HbA1c change was -6.6 mmol/mol (17.5 mmol/mol) versus -3.3 mmol/mol (10.9 mmol/mol) post-sham (p=0.033); 12-week post-DMR liver-fat change was -5.4% (6.1%) versus -2.2% (4.3%) post-sham (p=0.035). Brazilian mITT results trended towards DMR benefit in HbA1c, but not liver fat, in context of a large sham effect. In overall PP, patients with high baseline fasting plasma glucose ((FPG)≥10 mmol/L) had significantly greater reductions in HbA1c post-DMR versus sham (p=0.002). Most adverse events were mild and transient. Conclusions: DMR is safe and exerts beneficial disease-modifying metabolic effects in T2D with or without non-alcoholic liver disease, particularly in patients with high FPG. Trial registration number: NCT02879383.